You are here: Industry Insights > Allergan

News List

Allergan acquires neurotoxin specialist Bonti in $195m deal pharmafile
September 20, 2018
The Dublin-headquartered multinational Allergan have agreed to acquire the clinical stage biotech Bonti in a deal worth more than $195 million...
Allergan, Sosei suspend clinical development of dementia drug pharmatimes
September 20, 2018
Allergan and Sosei are voluntarily suspending clinical development activities with HTL0018318 pending investigation...
Allergan defuses Botox threat with $195M Bonti buy fiercebiotech
September 18, 2018
Bonti’s EB-001 works similarly to Botox, but it acts more quickly and its effects don’t last as long.
Allergan to Acquire Bonti americanpharmaceuticalreview
September 18, 2018
Allergan has agreed to acquire Bonti, a privately held clinical-stage biotechnology company focused on the development and commercialization of novel...
Allergan snaps up Bonti pharmatimes
September 18, 2018
Irish pharma Allergan is buying privately-held, clinical-stage US biotech Bonti for access to its novel, fast-acting neurotoxin programmes...
Allergan to Acquire Bonti for $195M contractpharma
September 17, 2018
Adds new neurotoxin programs to medical aesthetics pipeline
Allergan Receives Response Letter from FDA for Ulipristal Acetate americanpharmaceuticalreview
August 23, 2018
Allergan announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for ulipristal acetate (UPA) for the treatment of abnormal uterine bleeding in women with uterin
Allergan taps Pfizer oncology veteran as CMO for some crucial pipeline help fiercepharma
August 15, 2018
As Allergan enters a key phase for late-stage products crucial to its turnaround, it's poached a Pfizer veteran to help bring its plans to fruition.
Allergan, Editas Medicine to Jointly Develop EDIT-101 americanpharmaceuticalreview
August 08, 2018
Allergan and Editas Medicine announced Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10.....
Allergan divests five dermatology medicines to Almirall for $550m pharmaceutical-technology
August 07, 2018
Allergan has signed a definitive agreement to divest five products under its US Medical Dermatology division to Spanish pharmaceutical company Almirall for a cash consideration of $550m.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page